Research
Antibody-drug conjugate shows promising early results in Phase I trial in sarcoma patients
The Brief
- An antibody-drug conjugate showed promising early results in a Phase I trial in patients with soft tissue sarcoma.
- The results were seen across several types of soft tissue sarcoma.
- The findings were presented at the 38th EORTC-NCI-AACR Symposium.
Why it matters
Phase I trials mainly test safety and dosing, so these early signals suggest the approach may be worth pursuing in sarcoma, but efficacy is not yet established.
Who’s affected
- sarcoma patients
- oncologists and cancer researchers
- #antibody-drug conjugate
- #sarcoma
- #phase I trial
- #oncology
- #clinical trial
An antibody-drug conjugate, a type of drug that targets and enters cancer cells like a Trojan Horse, has shown promising early results across diverse types of soft tissue sarcoma in a Phase I trial. The findings were presented at the 38th EORTC-NCI-AACR Symposium on Molecular…